See the company's press release here. And see the posting from the CEO, Rehan Verjee, at Linked In here.
Here's an AI summary:
Precede Biosciences is a Boston-based molecular pathology and precision medicine startup focused on decoding detailed disease biology from a simple blood test using its comprehensive epigenomic liquid biopsy platform, which profiles circulating chromatin and the DNA methylome to reveal dynamic gene and pathway activity in diseased tissues from just 1 mL of plasma.
The company’s R&D goals center on enabling high-resolution insights into transcriptional biology to inform drug development, characterize response and resistance mechanisms, and ultimately develop minimally invasive blood-based diagnostics that could guide clinical decision-making and replace some tissue biopsies. Its platform is already being used in research settings and presented at major scientific meetings for applications in cancer and precision medicine.
Founded in 2021, Precede [had previously] raised roughly $57 million in venture and private equity funding from top investors including 5AM Ventures, Lilly Asia Ventures, Illumina Ventures, and others, supporting both platform scale-up and translational efforts.
The company’s CEO and co-founder, Rehan Verjee, brings strong life-science leadership experience from his prior executive roles in biopharmaceutical strategy and commercial operations, including serving on the Healthcare Executive Committee at Merck KGaA and as President of EMD Serono, where he helped guide business and product strategy—experience that positions him well to drive Precede’s growth at the intersection of innovative diagnostics and precision oncology.
###
Another Boston-based molecular pathology firm, Mercy BioAnalytics, raised $59M in Series B financing in September 2025. Focus is early cancer detection.
###
California-based Freenome announced in December a pending SPAC transaction which will raise over $300M in 1H2026. Here. See a January 12, 2026 announcement of a new collaboration between Freenome and Nvidia for deep learning approaches to cancer detection. Here.
California-based Freenome announced in December a pending SPAC transaction which will raise over $300M in 1H2026. Here. See a January 12, 2026 announcement of a new collaboration between Freenome and Nvidia for deep learning approaches to cancer detection. Here.
